
Dhruv Sareen, PhD
- The doctor practices in an office or specialty that we currently do not survey.
- The doctor has not yet received the minimum number of patient satisfaction surveys (30) to be eligible for display.

- The doctor practices in an office or specialty that we currently do not survey.
- The doctor has not yet received the minimum number of patient satisfaction surveys (30) to be eligible for display.
Dhruv Sareen, PhD
- The doctor practices in an office or specialty that we currently do not survey.
- The doctor has not yet received the minimum number of patient satisfaction surveys (30) to be eligible for display.

Dhruv Sareen, PhD
Languages
- English,
Gender
Male
Experience
Specialties
Area in which a healthcare provider is highly trained and often board certified.
1
- Research
Research Areas
Dhruv Sareen, PhD, is the founding director of the (IPSC) Core Facility at the Cedars-Sinai and founding executive director of the new Cedars-Sinai Biomanufacturing Center. He is also the principal investigator of his laboratory. He completed his undergraduate degree at the University of Mumbai, Institute of Chemical Technology. He then went on to complete his Ph.D. in biomolecular chemistry and post-doctoral work on stem cells and neuroscience at the University of Wisconsin, Madison. Dr. Sareen has extensive experience with human induced pluripotent stem cells (iPSC)-based disease models, cell signaling, mechanistic drug discovery, process development of early research discoveries, and optimizing cGMP-compatible stem cell therapies. As iPS cells are an excellent source for creating typically inaccessible patient cells (such as brain or heart cells) from a simple blood draw, they form a critical component of his research interests;. Through a process called "reprogramming," he and his team take adult human cells back in time to their embryonic beginnings, when they were pluripotent, or capable of making any cell type in the body. Then they engineer them forward, in a process called "differentiation," into specific cell types of the brain, heart, intestines, and other organs. Using the iPS cells from the patient they reanimate specific cells of the body in a dish to learn about mechanisms for their deterioration, use them for drug screening and design the next generation of cellular therapies. The Sareen laboratory uses stem cells (iPSCs) to model diseases and explore tomorrows therapeutics. By differentiating stem cells into mature cells such as neurons, gastric and pancreatic organoids with endocrine and exocrine cells, we study the cellular signaling that underlies some of today's most intractable diseases, including diabetes, pancreatitis, neurological diseases like ALS, and COVID-19. Using gene editing, bioprinting, and other emerging tools, we seek to correct defects in a dish and then bring those treatments to patients through process development and translational activities. His lab has published many papers using iPSC-based models to study these diseases. Dr. Sareen and his team in the iPSC Core have created a bank of over 800 iPSCs available to academic and commercial institutions. The cells have been distributed worldwide. Dr. Sareen also is the inventor on many patents related to technologies in the field of iPS cells. As the Executive Director of the CBC, Dr. Sareen has led the development and establishment of a state-of-the art cGMP facility. The CBC is comprised of a cGMP cell biomanufacturing labs housing multiple cleanroom suites for clinical-grade cell production to be tested in human IND-enabling clinical trials and a human iPSC line and differentiation lab with automation for commercial-grade manufacturing of iPSCs and their differentiated cell types for research purposes. Both labs within the center can serve academic, clinical and commercial investigators, providing a much-needed facility to develop and manufacture cell-based products suitable for investigational use in humans as well as for mechanistic drug discovery programs. Dr. Sareen strongly believes that modern therapeutic programs should form meaningful symbiotic partnerships between academic and industry partners even at a nascent stage of technology development.
Titles
- Executive Director, Cedars-Sinai Biomanufacturing Center
- Associate Professor, Biomedical Sciences
Achievements
-
6
Awards and Honors
-
6
Publications
Awards and Honors
- Travel Award, International Society for Stem Cell Research
- Harry Karavolas Graduate Student Scholarship
- Wisconsin Entrepreneurial Bootcamp Certificate, University of Washington School of Business
- International Society for Stem Cell Research
- Editorial Board: The Journal of Rare Disorders
- Society for Neuroscience
Publications
A full list of this provider’s research publications can be found on their research profile or PubMed.
- Sareen D, Svendsen CN. Stem cell biologists sure play a mean pinball. Nat Biotechnol. 2010 Apr;28(4):333-335.
- Sareen D, O'Rourke JG, Meera P, Muhammad AK, Grant S, Simpkinson M, Bell S, Carmona S, Ornelas L, et al. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci Transl Med. 2013 Oct 23;5(208):208ra149.
- Sareen D, Gowing G, Sahabian A, Staggenborg K, Paradis R, Avalos P, Latter J, Ornelas L, Garcia L, Svendsen CN. Human induced pluripotent stem cells are a novel source of neural progenitor cells (iNPCs) that migrate and integrate in the rodent spinal cord. J Comp Neurol. 2014 Aug 15;522(12):2707-2728.
- Sareen D, Ebert AD, Heins BM, McGivern JV, Ornelas L, Svendsen CN. Inhibition of apoptosis blocks human motor neuron cell death in a stem cell model of spinal muscular atrophy. PLoS One. 2012;7(6):e39113.
- Saitta B, Passarini J, Sareen D, Ornelas L, Sahabian A, Argade S, Krakow D, Cohn DH, Svendsen CN, Rimoin DL. Patient-derived skeletal dysplasia induced pluripotent stem cells display abnormal chondrogenic marker expression and regulation by BMP2 and TGFβ1. Stem Cells Dev. 2014 Jul 1;23(13):1464-1478.
- Ebert AD, Shelley BC, Hurley AM, Onorati M, Castiglioni V, Patitucci TN, Svendsen SP, Mattis VB, McGivern JV, Schwab AJ, Sareen D, et al. EZ spheres: a stable and expandable culture system for the generation of pre-rosette multipotent stem cells from human ESCs and iPSCs. Stem Cell Res. 2013 May;10(3):417-427.